Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Carcinoma, Hepatocellular 26Small Cell Lung Carcinoma 18Lung Neoplasms 15Neoplasms 13Breast Neoplasms 9Colorectal Neoplasms 7Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Melanoma 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Carcinoma, Transitional Cell 5Sarcoma 4Glioblastoma 4Stomach Neoplasms 3Solid Tumors 3Sarcoma, Alveolar Soft Part 3Ovarian Neoplasms 3Mesothelioma, Malignant 3Liver Neoplasms 3Extensive Stage Lung Small Cell Carcinoma 3Endometrial Neoplasms 3Carcinoma, Neuroendocrine 3Carcinoma 3Treatment-Refractory Solid Tumors 2Small Cell Lung Cancer Extensive Stage 2

Interventions

pembrolizumab 1liposomal doxorubicin 1atezolizumab 1Tumor Necrosis Factor-alpha 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoviridae Infections × atezolizumab × 90 days × Clear all
NCT07538128 2026-04-20

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Huashan Hospital

Phase EARLY_PHASE1 Recruiting
10 enrolled
CNS

Adenoviridae Infections, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡